<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154781">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990391</url>
  </required_header>
  <id_info>
    <org_study_id>0008.0.197.185-11</org_study_id>
    <secondary_id>U1111-1132-2061</secondary_id>
    <nct_id>NCT01990391</nct_id>
  </id_info>
  <brief_title>Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities</brief_title>
  <official_title>Effect of Brazil Nut Consumption in the Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities in Hypertensive and Dyslipidemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cardiologia de Laranjeiras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose this research is to check the effect of Brazil Nuts consumption in oxidative
      stress, metabolic abnormalities and microvascular endothelial function dyslipidemic and
      hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Antioxidant biomarker</measure>
    <time_frame>Change from Baseline at 12 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline plasma Gluthathione Peroxidase activity (nmol/min/ml)  at 12 weeks, samples were stocked at -80 degrees.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress biomarker</measure>
    <time_frame>Change from Baseline at 12 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline plasma 8-isoprostane (pg/ml) at 12 weeks, samples were stocked at -80 degrees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microvascular endothelial function</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Microvascular reactivity was evaluated using an Laser Speckle Contrast Imaging  system with a laser wavelength of 785 nm in combination with the iontophoresis (increasing anodal currents of 30, 60, 90, 120, 150 and 180Î¼A for 10 second intervals spaced 1 minute apart) of acetylcholine (2% v/v) for the noninvasive and continuous measurement of cutaneous microvascular perfusion changes measured in arbitrary perfusion units.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anthropometric measures</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>body weight (kg), body mass index (kg/m2) and waist circumference (cm).</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>total Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides (mg/dl).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Cassava flavored flour</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The  placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brazil nut flour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Brazil nut flour</intervention_name>
    <description>The Brazil nut group received 13g/day of Brazil nut flour during three months.</description>
    <arm_group_label>Cassava flavored flour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (cassava flavored flour)</intervention_name>
    <description>The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months</description>
    <arm_group_label>Brazil nut flour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults &gt; 20 years old

          -  Dyslipidemic

          -  Hypertensive

        Exclusion Criteria:

          -  Allergy to nuts

          -  Consumption of nuts or vitamins/minerals supplement

          -  Loss weight before the research

          -  pregnancy

          -  Kidney chronic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grazielle V B Huguenin, Nutricionist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Grazielle Vilas Boas Huguenin</investigator_full_name>
    <investigator_title>Mrs</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
